|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HIF1α degradation favors ccRCC proliferation, in line with the previously recognized tumor suppressor capability of HIF1α.
|
25915846 |
2016 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In immunoblot assays, the expression of HIF-1α was lowly detected in whole and nuclear lysates of RCC cell lines even under normoxia (20% O<sub>2</sub>), and their expression in whole lysates was increased under hypoxia (1% O<sub>2</sub>).
|
28110220 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HIF-1 and total HIF pathway activation scores were decreased with higher ascorbate in pRCC tumors (Spearman <i>r</i> = -0.38, <i>p</i> < 0.05 and <i>r</i> = -0.35, <i>p</i> < 0.05).This was not evident for ccRCC tumors.
|
30555801 |
2018 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HIF-1α, HIF-2α and CAIX were up-regulated in 88.2% (15/17), 100% (17/17) and 88.2% (15/17) of tumors respectively and their expression is independent of VHL status. hnRNP A2/B1 and osteopontin expression was variable in CCRCCs and had no association with VHL genetic status.
|
21547579 |
2011 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that the anti-angiogenic TKI sunitinib disrupted the balance between HIF-1α and HIF-2α in RCCs and led to a protective effect on HUVECs against sunitinib treatment when cultured with conditioned medium.
|
28572533 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Von Hippel‑Lindau tumor suppressor (VHL)‑hypoxia‑inducible factor 1 subunit α (HIF1A)/hypoxia‑inducible factor 2α (HIF2A)‑vascular endothelial growth factor A (VEGFA) protein axis is involved in the development and progression of ccRCC, whereas sunitinib, a tyrosine kinase inhibitor, blocks the binding of VEGFA to its receptor.
|
31268155 |
2019 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Inactivation of the VHL TSG in VHL tumours and in sporadic clear cell renal cell carcinoma (RCC) results in overexpression of HIF-1 and HIF-2.
|
15220362 |
2004 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, this study demonstrates that downregulation of HIF-1alpha could suppress tumorigenicity of RCC through induction of apoptosis, and HIF-1alpha shRNA may be a promising strategy for the treatment of RCC.
|
19816521 |
2010 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
It has also been reported that a single nucleotide polymorphism (SNP) in exon 12 of HIF-1alpha gene is present in renal cell carcinoma and head and neck squamous cell carcinoma patients.
|
15492789 |
2004 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Clear cell renal cell carcinoma (ccRCC) is characterized by stabilization of hypoxia-inducible factor (HIF1), and mutations in <i>von Hippel-Lindau</i> (<i>VHL</i>) gene.
|
29218250 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HIF-1alpha mRNA and protein upregulation involves Rho GTPase expression during hypoxia in renal cell carcinoma.
|
12697836 |
2003 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, the expression of LimD1, VHL and HIF1α was analyzed in primary renal cell carcinoma (RCC) samples to understand their association with development of the disease.
|
29033184 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, mammalian target of rapamycin (mTOR), an intracellular serine/threonine kinase, is also implicated in HIF-1a regulation, thus reinforcing the rationale for using mTOR inhibitors (rapamycin) in CCRCC.
|
20437403 |
2011 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effects of miR-138 or si-HIF-1a on ccRCC 786-O cells were also estimated by apoptosis analysis and cell migration assay.
|
21875287 |
2011 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A prospective, longitudinal cohort study was conducted with 50 patients diagnosed with clear-cell renal cell carcinoma to analyze VHL mutations and hypermethylation as well as VHL, HIF1-α, vascular endothelial growth factor (VEGF), ERK1/2, and ERK5 protein expression.
|
28624320 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The objective of this study was to evaluate the significance of 3p loss (loss VHL gene) and 14q loss (loss HIF-1α gene) in clear cell renal cell carcinoma (ccRCC).
|
23335244 |
2013 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HIF-2alpha promotes von Hippel-Lindau (VHL)-deficient renal clear cell carcinoma (RCC) tumorigenesis, while HIF-1alpha inhibits RCC growth.
|
17418410 |
2007 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study was to determine the effect of variation within microRNA (miRNA)-binding sites of genes in the VHL-HIF1α pathway on RCC risk.
|
22517515 |
2014 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, the Rho/Rho-associated kinase (ROCK) signaling has been shown to play a key role in HIF-1alpha induction in renal cell carcinoma and trophoblast.
|
18566226 |
2008 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We investigated the genetic changes in the VHL gene and HIF-1alpha and studied their clinical implications in patients with sporadic CC-RCC.
|
15809750 |
2005 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, in this study we investigate the relation between CD133 and nuclear HIF-1α expression levels in RCC tissues.
|
22614155 |
2012 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Subcellular CXCR4 and HIF-1α expression levels were independent adverse prognostic factors and could be combined with TNM stage to generate a predictive nomogram of the clinical outcome of patients with RCC.
|
30177838 |
2019 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these data suggest that PIG3 was involved in HIF-1α regulation, and reveal a novel signaling pathway of PIG3/HIF-1α in the regulation of cell migration in renal cell carcinoma.
|
27029070 |
2016 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings establish that activated HIF1α in murine kidney PT cells is sufficient to promote cell proliferation, angiogenesis, genomic instability, and other phenotypic alterations characteristic of human VHL kidney disease, establishing the TRACK mouse as a valid preclinical model of human renal cell carcinoma.
|
21908555 |
2011 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
VHL is a major tumour suppressor in ccRCC and loss of VHL leads to stabilisation of hypoxia inducible factors HIF-1α and HIF-2α.
|
29872221 |
2018 |